EPHB2 (EPH Receptor B2)

Importantly, ROF treatment significantly suppressed tumor growth in vivo without discernible toxicity. Rhoifolin exerts potent and selective anti-lung cancer activity by directly targeting and downregulating EPHB2, providing a strong rationale for its further development as a novel therapeutic agent for lung cancer.

Sorafenib, Salubrinal, and Roscovitine were positively correlated with the risk score, whereas WO2009093972 was negatively correlated. Additionally, this study identified several target genes such as FBXO25 with TINAG, CCDC28A with EPHB2, and SH2D6 with FCN3, with subsequent validation achieved through qPCR and western blotting. In conclusion, this study identifies three prognostic genes, providing new insights into CRC pathogenesis and potential therapeutic strategies.

Taken together, these findings spotlight the role of tumor-induced TME remodeling in subverting immune-mediated tumor control and thus facilitating HGSOC metastasis in females. Collectively, our results provide a foundation for the development of targeted therapeutic interventions aimed at impeding HGSOC metastatic trajectory.

In conclusion, our results highlight that a subset of EPHs and EFNs may be associated with worse clinical outcomes (EPHA4, EPHA5, EPHA7, EPHA8, EPHB2, EFNA2, and EFNB2), and an aggressive histological subtype (EPHA2, EPHA4, EPHA8, EPHB4, EFNA1, EFNA3, EFNA4, and EFNB2). The potential correlation of these genes with clinicopathological parameters of UVM need to be evaluated and validated with bioinformatic and experimental approaches in well-characterized cohorts of UVM patients.

In conclusion, Atractylodis Macrocephalae Rhizoma stir-fried with Aurantii Fructus prepared by Menghe medical school could treat UC due to spleen deficiency with dampness retention induced by the method of internal and external factors + TNBS in rats. Specifically, it can up-regulate the expression of RNF186 and modulate EPHB2 ubiquitination to activate intestinal autophagy, repair intestinal epithelial barrier, and relieve intestinal inflammatory damage.

The constructed prognostic model by NETs and oxidative stress-relevant genes effectively predicts LUAD prognosis, correlates with immune microenvironment characteristics, and guides drug sensitivity, providing novel insights for LUAD prognostic assessment and personalized therapy.

Serum EphB2 represents a promising diagnostic and prognostic biomarker for NPC. The combination of EBV seropositivity and high EphB2 expression may be valuable for early NPC screening.

This study systematically investigates EPHB2 as a potential biomarker through comprehensive bioinformatics (TIMER 2.0, Human Protein Atlas, Xanadu Academic Online, Sento Academic Online, TCGA, GeneMANIA, GSEA, BEST database, and SCAR database) and experimental analyses (si-EPHB2 and OE-EPHB2 RL95-2 cell models with RT-qPCR, western blot, CCK-8, wound healing, Transwell, and TUNEL assays). Our findings demonstrate that EPHB2 is significantly overexpressed in EC, correlating with advanced pathological grade, histological type, and poor prognosis, while its high expression activates PI3K/AKT/MAPK signaling and promotes proliferation, migration, invasion, and suppresses apoptosis; conversely, EPHB2 knockdown exhibits opposite effects, revealing its critical role in EC progression through immune modulation and oncogenic signaling activation, thereby establishing EPHB2 as a promising therapeutic target for EC treatment.

Critically, tumor suppressor SH3BP1 (a key regulator) correlates with reduced tumor progression and enhanced CD8+ T cell anti-tumor immunity when highly expressed. These findings underscore that SH3BP1 may represent a promising therapeutic target for precise intervention in GMS-immune interactions in GC.

QUAD-DM1 is a novel multivalent drug conjugate that appears to be highly suitable for the treatment of breast cancer and related brain metastases. The drug candidate can be administered systemically, due to its favorable toxicity profile, or loco-regionally.

NRG was proved to be an accurate predictor of CRC prognosis. Furthermore, the novel signature exhibited consistent value and translational potential for predicting prognosis, tumor immunogenicity, and therapeutic response in CRC.

EPHB2 and TOP2A serve as bridge genes linking SLE and CRC, offering insights into their molecular interplay and the potential for developing new diagnostic markers and therapeutic targets. Future studies should validate these findings and explore the detailed molecular mechanisms.